College of Life and Environmental Sciences, University of Exeter Exeter, UK.
Front Cell Infect Microbiol. 2013 Mar 25;3:13. doi: 10.3389/fcimb.2013.00013. eCollection 2013.
Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens.
疫苗接种对传染病的控制产生了重大影响。然而,仍有许多传染病,其有效疫苗的开发仍难以实现。在许多情况下,疫苗候选物无法引起适当的免疫反应是导致无法设计疫苗的原因。在需要细胞免疫来提供保护性免疫的情况下,这个问题尤其严重,而这种情况又因转向设计亚单位疫苗而变得更加复杂。在过去的十年中,纳米级(<1000nm)大小的材料,如病毒样颗粒、脂质体、免疫刺激复合物、聚合物和不可降解的纳米球,已作为疫苗抗原的潜在传递载体受到关注,这些载体既能稳定疫苗抗原,又能充当佐剂。重要的是,其中一些纳米颗粒(NPs)能够通过不同途径进入抗原呈递细胞,从而调节对抗原的免疫反应。这对于诱导针对细胞内病原体的保护性 Th1 型免疫反应可能至关重要。它们的特性还使它们适合在黏膜表面和皮内给药时传递抗原。在这篇综述中,我们比较了不同 NP 系统在亚单位疫苗传递方面的效用,并评估了这些传递系统在开发针对一系列病原体的新型疫苗方面的潜力。
Front Cell Infect Microbiol. 2013-3-25
Crit Rev Ther Drug Carrier Syst. 2019
Pharm Nanotechnol. 2020
Int J Pharm. 2019-10-24
Front Immunol. 2018-10-4
Drug Dev Ind Pharm. 2019-3-1
J Microbiol Biotechnol. 2019-3-28
Pharmaceutics. 2025-7-25
Vaccines (Basel). 2025-1-27
Vaccines (Basel). 2024-11-27
Vaccines (Basel). 2024-9-27
Vaccines (Basel). 2024-8-22
Mol Biotechnol. 2013-1
Eur J Pharm Biopharm. 2011-9-22